Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 6/20 | 0.31 |
| ▸ | CCND1 | P24385 | 6/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25045527 | 0.76 | — | — | |
| SCHEMBL13836115 | 0.76 | PSMD14 (0.37) | CMA1CDK4CCND1PRKCIPTPN11 | |
| SCHEMBL30109166 | 0.76 | MEN1 (0.41) | CMA1PTPN11NR3C1PGRCCR5 | |
| SCHEMBL436336 | 0.76 | MEN1 (0.41) | CMA1PTPN11NR3C1PGRCCR5 | |
| SCHEMBL4387353 | 0.74 | PRKCI (0.39) | CMA1PRKCIPTPN11 | |
| SCHEMBL29989147 | 0.74 | CDK4 (0.41) | CMA1CDK4CCND1PRKCICCNE2 | |
| SCHEMBL2625811 | 0.74 | CDK4 (0.41) | CMA1CDK4CCND1PRKCICCNE2 | |
| SCHEMBL30847966 | 0.74 | PRKCI (0.39) | CMA1PRKCIPTPN11 | |
| SCHEMBL2052186 | 0.74 | CYP1A2 (0.38) | CMA1CDK2 | |
| SCHEMBL2178459 | 0.74 | CDK4 (0.43) | CMA1TAF1BRPF1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11569460-B2 | Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-01-31 | — | — | US | disclosed |
| US-10988495-B2 | Organometallic compound, organic-light emitting device including the same, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-20190225636-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-07-25 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20190135844-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-20190140192-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | disclosed |
| WO-2009084501-A1 | SULTAM DERIVATIVE | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CMA1 3396/4885BRD4 986/4885TAF1 2583/4885 |
| US-20190135844-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | ORC3, ORMDL3, OR10J3 | CMA1 3348/4885BRD4 2366/4885TAF1 336/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CMA1 3396/4885BRD4 986/4885TAF1 2583/4885 |
| US-10988495-B2 | Organometallic compound, organic-light emitting device including the same, and diagnostic composition including the organometallic compound | CCNT1, TTI1, MEN1 | CMA1 3243/4885BRD4 2228/4885TAF1 142/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CMA1 3396/4885BRD4 986/4885TAF1 2583/4885 |
| US-20190140192-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | L1CAM, L3MBTL1, MSL1 | CMA1 2559/4885BRD4 2465/4885TAF1 934/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CMA1 3396/4885BRD4 986/4885TAF1 2583/4885 |
| US-20190225636-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | LEF1, ORC3, OCIAD1 | CMA1 3304/4885BRD4 2260/4885TAF1 144/4885 |
| US-11569460-B2 | Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound | L1CAM, L3MBTL1, MSL1 | CMA1 2559/4885BRD4 2465/4885TAF1 934/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CMA1 3396/4885BRD4 986/4885TAF1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.